Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
Lynn JongenGiuseppe FlorisBram BoeckxDominiek SmeetsDiether LambrechtsSara Vander BorghtAnnouschka LaenenGrace MannRichard E CutlerAlshad S LalaniPatrick NevenHans P M W WildiersPublished in: Breast cancer research and treatment (2018)
ERBB2mut+ are rare in patients in whom mBC developed and no evidence was found for an association with specific types of BC or patient characteristics, although outcomes of ERBB2mut+ carriers might be worse. The latter, however, needs to be validated in larger populations.
Keyphrases
- tyrosine kinase
- epidermal growth factor receptor
- metastatic breast cancer
- end stage renal disease
- advanced non small cell lung cancer
- endothelial cells
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- chronic kidney disease
- prognostic factors
- type diabetes
- gene expression
- dna methylation
- induced pluripotent stem cells
- metabolic syndrome
- skeletal muscle
- patient reported
- insulin resistance
- bioinformatics analysis